Masimo Receivables 2010-2024 | MASI

Masimo receivables for the quarter ending June 30, 2024 were $0.338B, a 3.18% decline year-over-year.

  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.
  • Masimo receivables for 2021 were $0.201B, a 42.06% increase from 2020.

Masimo Receivables 2010-2024 | MASI

  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.
  • Masimo receivables for 2021 were $0.201B, a 42.06% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.1B
Intuitive Surgical (ISRG)$171.3B
Alcon (ALC)$47.7B
IQVIA Holdings (IQV)$44.2B
IDEXX Laboratories (IDXX)$42.1B
Edwards Lifesciences (EW)$40.7B
DexCom (DXCM)$27.8B
STERIS (STE)$23.5B
SONOVA HOLDING (SONVY)$20.8B
Waters (WAT)$19.8B
Hologic (HOLX)$19B
Sysmex ADR (SSMXY)$12.3B
Fresenius Medical Care AG KGaA (FMS)$12.2B
Teleflex (TFX)$11.4B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.6B
Glaukos (GKOS)$6.7B
TransMedics (TMDX)$5.2B
PROCEPT BioRobotics (PRCT)$4.3B
Integer Holdings (ITGR)$4.3B
Tandem Diabetes Care (TNDM)$2.8B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.6B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.6B
Nihon Kohden (NHNKY)$2.5B
RxSight (RXST)$2B
Integra LifeSciences Holdings (IART)$1.4B
Pulse Biosciences (PLSE)$1.2B
OPKO Health (OPK)$1.1B